Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$7.88 -0.8%	$7.53	$5.01 ▼ $18.71	$47.33M	0.19	123,539 shs	16,739 shs
OMGA Omega Therapeutics	$0.13 -21.8%	$0.12	$0.10 ▼ $2.63	$6.92M	1.65	3.42 million shs	4.81 million shs
SOPH SOPHiA GENETICS	$3.05 +0.3%	$2.98	$2.58 ▼ $4.92	$202.73M	1	59,701 shs	51,242 shs
ZURA Zura Bio	$1.12 -0.9%	$1.21	$0.97 ▼ $5.07	$77.26M	-0.12	440,188 shs	328,513 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	-0.76%	-8.16%	+10.36%	+13.87%	-4.25%
OMGA Omega Therapeutics	0.00%	0.00%	0.00%	0.00%	-94.86%
SOPH SOPHiA GENETICS	+0.33%	+5.54%	+7.02%	-2.24%	-35.38%
ZURA Zura Bio	-0.88%	-6.67%	+9.80%	-24.83%	-67.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRA Atara Biotherapeutics	4.0037 of 5 stars	3.3	3.0	4.7	0.6	2.5	0.6
OMGA Omega Therapeutics	2.2075 of 5 stars	3.4	0.0	0.0	1.1	1.7	1.3
SOPH SOPHiA GENETICS	1.5415 of 5 stars	3.4	3.0	0.0	0.6	0.0	0.6
ZURA Zura Bio	2.5107 of 5 stars	3.6	1.0	0.0	1.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	125.25% Upside
OMGA Omega Therapeutics	2.80	Moderate Buy	$8.50	6,700.00% Upside
SOPH SOPHiA GENETICS	2.75	Moderate Buy	$6.80	122.95% Upside
ZURA Zura Bio	3.13	Buy	$14.33	1,179.76% Upside

Current Analyst Ratings Breakdown

Latest ATRA, ZURA, SOPH, and OMGA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
3/26/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $19.00
3/26/2025	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$128.94M	0.36	N/A	N/A	($16.89) per share	-0.47
OMGA Omega Therapeutics	$8.10M	0.85	N/A	N/A	$1.05 per share	0.12
SOPH SOPHiA GENETICS	$65.17M	3.12	N/A	N/A	$1.48 per share	2.06
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	-$85.40M	-$3.72	N/A	N/A	N/A	-7.83%	N/A	-14.51%	8/11/2025 (Estimated)
OMGA Omega Therapeutics	-$97.43M	-$1.33	N/A	N/A	N/A	-902.93%	-213.13%	-41.24%	N/A
SOPH SOPHiA GENETICS	-$62.49M	-$1.00	N/A	N/A	N/A	-98.51%	-63.47%	-40.06%	8/5/2025 (Estimated)
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-42.84%	-35.22%	8/12/2025 (Estimated)

Latest ATRA, ZURA, SOPH, and OMGA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
5/6/2025	Q1 2025	SOPH SOPHiA GENETICS	-$0.21	-$0.26	-$0.05	-$0.26	$16.76 million	$17.78 million
3/25/2025	Q4 2024	ZURA Zura Bio	-$0.17	-$0.08	+$0.09	-$0.08	N/A	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
OMGA Omega Therapeutics	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	0.57	0.57
OMGA Omega Therapeutics	1.00	1.61	1.61
SOPH SOPHiA GENETICS	0.16	3.11	2.94
ZURA Zura Bio	N/A	8.14	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
OMGA Omega Therapeutics	97.47%
SOPH SOPHiA GENETICS	31.59%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	4.00%
OMGA Omega Therapeutics	8.50%
SOPH SOPHiA GENETICS	4.88%
ZURA Zura Bio	22.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	5.96 million	5.72 million	Optionable
OMGA Omega Therapeutics	120	55.37 million	50.66 million	Optionable
SOPH SOPHiA GENETICS	520	66.69 million	63.43 million	Not Optionable
ZURA Zura Bio	3	68.38 million	53.26 million	Optionable

ATRA, ZURA, SOPH, and OMGA Headlines

Recent News About These Companies

Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Average PT from Analysts

June 21 at 1:35 AM | americanbankingnews.com

Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Buy" by Analysts

June 18, 2025 | marketbeat.com

Cantor Fitzgerald Weighs in on Zura Bio FY2026 Earnings

June 11, 2025 | marketbeat.com

Millennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA)

June 3, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by Brokerages

May 26, 2025 | marketbeat.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.com

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 26, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

Zura Bio Highlights Strategic Goals and Clinical Advances

January 13, 2025 | tipranks.com

Zura Bio initiates Phase II systemic sclerosis treatment trial

December 25, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA, ZURA, SOPH, and OMGA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$7.88 -0.06 (-0.76%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$7.89 +0.01 (+0.13%)

As of 06/23/2025 04:14 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Omega Therapeutics NASDAQ:OMGA

$0.12 -0.03 (-21.83%)

Closing price 02/24/2025

Extended Trading

$0.12 0.00 (0.00%)

As of 02/24/2025 07:59 PM Eastern

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

SOPHiA GENETICS NASDAQ:SOPH

$3.05 +0.01 (+0.33%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$3.06 +0.01 (+0.16%)

As of 06/23/2025 04:04 PM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Zura Bio NASDAQ:ZURA

$1.12 -0.01 (-0.88%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$1.14 +0.01 (+1.34%)

As of 06/23/2025 04:10 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time